Zooming in on the schedule of bone-modifying drugs
- PMID: 23684410
- DOI: 10.1016/S1470-2045(13)70209-2
Zooming in on the schedule of bone-modifying drugs
Comment on
-
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.Lancet Oncol. 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16. Lancet Oncol. 2013. PMID: 23684411 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
